Cambridge Investment Research Advisors’s Beam Therapeutics BEAM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+6,528	New	+$197K	﹤0.01%	3717
2025 Q2	–	Sell	-10,123	Closed	-$198K	–	3628
2025 Q1	$198K	Sell	10,123 -455	-4%	-$11.9K	﹤0.01%	3215
2024 Q4	$262K	Buy	10,578 +143	+1%	+$3.65K	﹤0.01%	2950
2024 Q3	$256K	Buy	+10,435	New	+$270K	﹤0.01%	2946
2023 Q1	–	Sell	-5,658	Closed	-$221K	–	3162
2022 Q4	$221K	Buy	5,658 +197	+4%	+$8.82K	﹤0.01%	2669
2022 Q3	$260K	Buy	+5,461	New	+$312K	﹤0.01%	2484
2022 Q1	–	Sell	-2,616	Closed	-$208K	–	3168
2021 Q4	$208K	Sell	2,616 -867	-25%	-$74.2K	﹤0.01%	2861
2021 Q3	$303K	Sell	3,483 -4,136	-54%	-$416K	﹤0.01%	2458
2021 Q2	$981K	Buy	7,619 +4,306	+130%	+$343K	﹤0.01%	1548
2021 Q1	$265K	Sell	3,313 -513	-13%	-$48.8K	﹤0.01%	2373
2020 Q4	$312K	Buy	+3,826	New	+$188K	﹤0.01%	2101

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Cambridge Investment Research Advisors's BEAM Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 6,528 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #3717 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in BEAM as recently as Q1 2025.

Cambridge Investment Research Advisors first reported a position in BEAM in Q4 2020 and has held it in 11 quarters since. The position peaked at $981K in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Cambridge Investment Research Advisors held 6,528 shares of Beam Therapeutics worth $224K as of Q2 2026.
Beam Therapeutics was a new Cambridge Investment Research Advisors position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3717 holding.
Cambridge Investment Research Advisors first reported a position in Beam Therapeutics in Q4 2020 and has held it in 11 quarters since.
Cambridge Investment Research Advisors's Beam Therapeutics position peaked at $981K in Q2 2021.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.